Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 44,679 shares at $0.54 ($24K) on 2026-05-13, disclosed to the SEC on 2026-05-13.
Scheduled sale ($24k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |